|
DCF -Bewertung der Talis Biomedical Corporation (TLIS)
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Talis Biomedical Corporation (TLIS) Bundle
Unabhängig davon, ob Sie ein Investor oder Analyst sind, ist dieser (TLIS) DCF-Taschenrechner Ihre Anlaufstelle für eine genaue Bewertung. Mit den tatsächlichen Daten der Talis Biomedical Corporation können Sie Prognosen anpassen und die Auswirkungen sofort beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.0 | 10.9 | .0 | 3.7 | .4 | .3 | .2 | .2 | .2 | .1 |
| Revenue Growth, % | 0 | 175.03 | -100 | 0 | -88.72 | -22.18 | -22.18 | -22.18 | -22.18 | -22.18 |
| EBITDA | -26.0 | -90.4 | -191.8 | -106.3 | -66.0 | -.2 | -.1 | -.1 | -.1 | -.1 |
| EBITDA, % | -653.08 | -826.67 | 100 | -2910.98 | -16030.34 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .7 | 1.4 | 2.6 | 11.6 | .8 | .2 | .2 | .1 | .1 | .1 |
| Depreciation, % | 18.25 | 12.56 | 100 | 317.66 | 186.89 | 66.16 | 66.16 | 66.16 | 66.16 | 66.16 |
| EBIT | -26.7 | -91.8 | -194.4 | -117.9 | -66.8 | -.2 | -.1 | -.1 | -.1 | -.1 |
| EBIT, % | -671.34 | -839.23 | 100 | -3228.64 | -16217.23 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 21.6 | 138.5 | 232.5 | 130.2 | 76.7 | .3 | .2 | .2 | .2 | .1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.8 | .5 | .2 | .3 | .1 | .1 | .1 | .1 | .1 | .0 |
| Account Receivables, % | 45.41 | 4.31 | 100 | 8.43 | 12.14 | 34.06 | 34.06 | 34.06 | 34.06 | 34.06 |
| Inventories | .0 | 46.7 | .0 | .0 | .0 | .1 | .1 | .1 | .1 | .0 |
| Inventories, % | 0 | 426.62 | 100 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 1.6 | 4.9 | 5.1 | 3.8 | 1.3 | .2 | .2 | .1 | .1 | .1 |
| Accounts Payable, % | 39.38 | 44.85 | 100 | 103.18 | 325 | 76.85 | 76.85 | 76.85 | 76.85 | 76.85 |
| Capital Expenditure | -.6 | -8.2 | -2.9 | -1.6 | -.5 | -.1 | -.1 | -.1 | -.1 | -.1 |
| Capital Expenditure, % | -14.53 | -74.98 | 100 | -44.22 | -117.96 | -46.75 | -46.75 | -46.75 | -46.75 | -46.75 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -26.7 | -91.7 | -192.8 | -115.7 | -66.8 | -.2 | -.1 | -.1 | -.1 | -.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -26.8 | -140.6 | -145.9 | -107.2 | -68.7 | -1.4 | -.1 | -.1 | -.1 | .0 |
| WACC, % | 4.99 | 4.99 | 4.96 | 4.93 | 4.99 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -2 | |||||||||
| Present Terminal Value | -1 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | -57 | |||||||||
| Equity Value | 54 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | 29.81 |
What You Will Get
- Real TLIS Financial Data: Pre-filled with Talis Biomedical Corporation’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Talis Biomedical Corporation’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Talis Biomedical Corporation (TLIS).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to Talis Biomedical Corporation (TLIS).
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit your analysis for Talis Biomedical Corporation (TLIS).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Talis Biomedical Corporation (TLIS).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis of Talis Biomedical Corporation (TLIS).
How It Works
- Step 1: Download the prebuilt Excel template featuring Talis Biomedical Corporation’s (TLIS) data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify the forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Talis Biomedical Corporation’s intrinsic value.
- Step 5: Make well-informed investment choices or create reports based on the outputs.
Why Choose This Calculator?
- Accurate Data: Real Talis Biomedical Corporation (TLIS) financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
- Time-Saving: Pre-built calculations eliminate the need to start from scratch.
- Professional-Grade Tool: Designed for investors, analysts, and consultants.
- User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.
Who Should Use Talis Biomedical Corporation (TLIS)?
- Investors: Gain insights into innovative diagnostics and make informed investment choices.
- Healthcare Professionals: Utilize cutting-edge technology to enhance patient care and diagnostics.
- Research Analysts: Streamline your analysis with comprehensive data on Talis Biomedical's offerings.
- Biotechnology Enthusiasts: Explore advancements in molecular diagnostics through real-world applications.
- Students and Educators: Leverage the company's innovations as case studies in biotechnology and healthcare courses.
What the Template Contains
- Pre-Filled DCF Model: Talis Biomedical Corporation’s (TLIS) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Talis Biomedical Corporation’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.